当前位置：
X-MOL 学术
›
Bone Marrow Transpl.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Bone Marrow Transplantation ( IF 4.5 ) Pub Date : 2019-11-06 , DOI: 10.1038/s41409-019-0732-9 E Domingo-Domènech 1 , A Boumendil 2 , F Climent 3 , G Socié 4 , F Kroschinsky 5 , H Finel 2 , E Vandenbergue 6 , D Nemet 7 , M Stelljes 8 , J T Bittenbring 9 , S Robinson 10 , S Montoto 11 , A Sureda 1 , P Dreger 12 ,
Bone Marrow Transplantation ( IF 4.5 ) Pub Date : 2019-11-06 , DOI: 10.1038/s41409-019-0732-9 E Domingo-Domènech 1 , A Boumendil 2 , F Climent 3 , G Socié 4 , F Kroschinsky 5 , H Finel 2 , E Vandenbergue 6 , D Nemet 7 , M Stelljes 8 , J T Bittenbring 9 , S Robinson 10 , S Montoto 11 , A Sureda 1 , P Dreger 12 ,
Affiliation
|
Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with relapsed/refractory sALCL with special emphasis on the role of brentuximab vedotin (BV) as a bridge to allo-HCT. Forty-four patients (24 females, median age 38 years) with sALCL were included. Twenty-three patients (52%) received BV before allo-HCT; BV-treated patients were more heavily pretreated (≥3 lines of therapy in 74% vs. 38%, p = 0.04). Twenty-three patients (52%) were in complete remission (CR) at allo-HCT. Three-year nonrelapse mortality and incidence of relapse (IR) after allo-HCT were 7% and 40%, respectively. With a median follow-up of 39 (12-69) months for survivors, 3-year progression-free survival (PFS) and overall survival were 53% and 74%, respectively. Univariate analysis showed that heavily pretreated patients and those not in CR had a higher IR and a lower PFS. The use of BV before transplant did not impact on any of the outcomes. Allo-HCT is a curative therapeutic strategy in a significant proportion of patients with relapsed/refractory sALCL; BV does not seem to modify transplant-related outcomes but might be able to render more patients candidates for this curative treatment.
中文翻译：
异基因造血干细胞移植用于复发/难治性系统间变性大细胞淋巴瘤患者。欧洲血液和骨髓移植学会淋巴瘤工作组的回顾性分析。
关于异基因干细胞移植（allo-HCT）在系统性间变性大细胞淋巴瘤（sALCL）中的治疗作用的信息很少。我们分析了alo-HCT在复发/难治性sALCL患者中的结果，特别强调了brentuximab vedotin（BV）作为通向allo-HCT的桥梁的作用。包括sALCL的44例患者（24名女性，中位年龄38岁）。23名患者（52％）在进行异基因HCT之前接受了BV治疗；BV治疗的患者接受了更严格的预治疗（≥3种疗法的治疗率分别为74％和38％，p = 0.04）。23例（52％）患者在allo-HCT完全缓解（CR）。异基因HCT治疗后的三年非复发死亡率和复发率分别为7％和40％。对幸存者进行的中位随访时间为39（12-69）个月，3年无进展生存期（PFS）和总生存期分别为53％和74％。单因素分析表明，经过大量预处理的患者和未接受CR的患者IR较高，PFS较低。移植前使用BV不会影响任何预后。Allo-HCT是相当多的sALCL复发/难治性患者的治愈性治疗策略；BV似乎并没有改变与移植相关的结果，但可能能够使更多的患者接受这种治疗。
更新日期：2019-11-06
中文翻译：
异基因造血干细胞移植用于复发/难治性系统间变性大细胞淋巴瘤患者。欧洲血液和骨髓移植学会淋巴瘤工作组的回顾性分析。
关于异基因干细胞移植（allo-HCT）在系统性间变性大细胞淋巴瘤（sALCL）中的治疗作用的信息很少。我们分析了alo-HCT在复发/难治性sALCL患者中的结果，特别强调了brentuximab vedotin（BV）作为通向allo-HCT的桥梁的作用。包括sALCL的44例患者（24名女性，中位年龄38岁）。23名患者（52％）在进行异基因HCT之前接受了BV治疗；BV治疗的患者接受了更严格的预治疗（≥3种疗法的治疗率分别为74％和38％，p = 0.04）。23例（52％）患者在allo-HCT完全缓解（CR）。异基因HCT治疗后的三年非复发死亡率和复发率分别为7％和40％。对幸存者进行的中位随访时间为39（12-69）个月，3年无进展生存期（PFS）和总生存期分别为53％和74％。单因素分析表明，经过大量预处理的患者和未接受CR的患者IR较高，PFS较低。移植前使用BV不会影响任何预后。Allo-HCT是相当多的sALCL复发/难治性患者的治愈性治疗策略；BV似乎并没有改变与移植相关的结果，但可能能够使更多的患者接受这种治疗。
京公网安备 11010802027423号